[
1. Amin MB., Edge SB, Greene FL et al., editors. AJCC cancer staging manual, 8th ed.; 2017:351-419.10.1007/978-3-319-40618-3
]Search in Google Scholar
[
2. Wang Y, Wang W, Jin K, Fang C, Lin Y, Xue L et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide longacting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors. Oncol Lett. 2017;13(3):1165-74.10.3892/ol.2017.5591540348628454229
]Search in Google Scholar
[
3. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Müller-Nordhorn J, et al. Neuroendocrine tumors of midgut and hindgut origin: Tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117:3332-41.10.1002/cncr.2585521246527
]Search in Google Scholar
[
4. Klöppel G, Couvelard A, Hurban RH. Neoplasms of the neuroendocrinae pancreas in WHO classification of tumors of endocrine organs, 4th ed., IARC, 2017; 211-4.
]Search in Google Scholar
[
5. Kruljac I, Pape UF. The classification of neuroendocrine neoplasms: „Neuroendocrine carcinomas“ revisited – a 2017 update and future perspectives. Endocr Oncol Metab. 2017;3(2): 37-42.
]Search in Google Scholar
[
6. Perren A, Couvelard A, Scoazec J, Costa F, Borbath I, Delle Fave G et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology. 2017;105(3):196-200.10.1159/00045795628190015
]Search in Google Scholar
[
7. Bosman F, Carneiro F, Hruban R, Theise N: WHO classification of tumors of the digestive system, 4 ed. Lyon: IARC Press; 2010.
]Search in Google Scholar
[
8. Capelli P, Fassan M, Scarpa A Pathology – grading and staging of GEP-NET. Best Pract Res Clin Gastroenterol. 2012;26(6):705-17.10.1016/j.bpg.2013.01.00323582914
]Search in Google Scholar
[
9. Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):68-81.10.1093/annonc/mdv50526487581
]Search in Google Scholar
[
10. Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos MFKP, Jacob CE et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig. 2017;30(2):150-4.10.1590/0102-6720201700020016554379729257854
]Search in Google Scholar
[
11. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11-6.10.1016/j.anndiagpath.2017.04.00528807335
]Search in Google Scholar
[
12. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinol. 2012;95(2):98-119.10.1159/000335591370144922261919
]Search in Google Scholar
[
13. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(4068):77-9.10.1126/science.179.4068.774682131
]Search in Google Scholar
[
14. Kiviniemi A, Gardberg M, Kivinen K, Posti JP, Vuorinen V, Sipilä J, et al. Somatostatin receptor 2A in gliomas: association with oligodendrogliomas and favourable outcome. Oncotarget. 2017;8(30):49123-32.10.18632/oncotarget.17097556475428467778
]Search in Google Scholar
[
15. Öberg K and Lamberts SWJ. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer. 2016; 23(12):R551-R566.10.1530/ERC-16-015127697899
]Search in Google Scholar
[
16. Herac M, Niederle B, Raderer M, Krebs M, Kaserer K, Koperek O. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis. APMIS. 2016;124:839-45.10.1111/apm.1258427539746
]Search in Google Scholar
[
17. Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, et al. Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45(10):1386-93.10.1097/MPA.0000000000000700506797227622342
]Search in Google Scholar
[
18. Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V et al Gastrinoma (duodenal and pancreatic). Neuroendocrinol. 2006;84(3):173-82.
]Search in Google Scholar
[
19. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199-203.10.1126/science.1200609314449621252315
]Search in Google Scholar
[
20. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol. 2022;33(1):115-54.10.1007/s12022-022-09708-235294740
]Search in Google Scholar
[
21. Fang JM, Shi J. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. Arch Pathol Lab Med. 2019;143(11):1317-26.10.5858/arpa.2019-0338-RA714176031509453
]Search in Google Scholar
[
22. Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther. 2018;18(9):837-60.10.1080/14737140.2018.1496822628341029973077
]Search in Google Scholar
[
23. La Rosa S, Uccella S. Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord. 2021;22(3):527-38.10.1007/s11154-020-09612-2834645133169199
]Search in Google Scholar
[
24. Li MX, Wang HY, Yuan CH, Ma CL, Jiang B, Li L,et al. The eighth version of American Joint Committee on Cancer nodal classification for high grade pancreatic neuroendocrine tumor should be generalized for the whole population with this disease. Medicine (Baltimore). 2020;99(37):e22089.10.1097/MD.0000000000022089748959732925749
]Search in Google Scholar
[
25. Oka N, Kasajima A, Konukiewitz B, Sakurada A, Okada Y, Kameya T, et al. Classification and Prognostic Stratification of Bronchopulmonary Neuroendocrine Neoplasms. Neuroendocrinol. 2020;110(5):393-403.10.1159/00050277631422400
]Search in Google Scholar
[
26. Păun I, Becheanu G, Costin AI, Constantin VD, Mihai GM, Radu L, et al. Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system - a review. Rom J Morphol Embryol. 2018;59(3):673-78.
]Search in Google Scholar
[
27. Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47(3):463-70.10.1016/j.ecl.2018.04.00830098710
]Search in Google Scholar
